(Q47689697)

4 February 2018

title

Tau-based therapies in neurodegeneration: opportunities and challenges (English)

1 reference

4 February 2018

1 reference

Chuanzhou Li

1

1 reference

4 February 2018

Jürgen Götz

series ordinal

2

1 reference

4 February 2018

publication date

6 October 2017

1 reference

4 February 2018

Nature Reviews Drug Discovery

published in

1 reference

4 February 2018

volume

16

1 reference

4 February 2018

issue

12

1 reference

4 February 2018

page(s)

863-883

1 reference

4 February 2018

https://scigraph.springernature.com/pub.10.1038/nrd.2017.155

exact match

0 references

cites work

Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Alzheimer's pathology in human temporal cortex surgically excised after severe brain injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Increasing the efficiency of CRISPR/Cas9-mediated precise genome editing in rats by inhibiting NHEJ and using Cas9 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Brain-Region-Specific Organoids Using Mini-bioreactors for Modeling ZIKV Exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

ptl-1, a Caenorhabditis elegans gene whose products are homologous to the tau microtubule-associated proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

PTL-1 regulates neuronal integrity and lifespan in C. elegans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Nuclear tau, a key player in neuronal DNA protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

The Human Tau Interactome: Binding to the Ribonucleoproteome, and Impaired Binding of the Proline-to-Leucine Mutant at Position 301 (P301L) to Chaperones and the Proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Amyloid Precursor Protein (APP) Metabolites APP Intracellular Fragment (AICD), Aβ42, and Tau in Nuclear Roles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

The frontotemporal dementia mutation R406W blocks tau's interaction with the membrane in an annexin A2-dependent manner.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Phosphorylation of tau by fyn: implications for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Lysosomal dysfunction promotes cleavage and neurotoxicity of tau in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Tau phosphorylation at serine 396 residue is required for hippocampal LTD

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Activity-dependent tau protein translocation to excitatory synapse is disrupted by exposure to amyloid-beta oligomers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Differential regulation of dynein and kinesin motor proteins by tau

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Posttranslational modifications of tau--role in human tauopathies and modeling in transgenic animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Identification of an aggregation-prone structure of tau.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Novel diffusion barrier for axonal retention of Tau in neurons and its failure in neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Tau phosphorylation sites work in concert to promote neurotoxicity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

The acetylation of tau inhibits its function and promotes pathological tau aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Dual modification of Alzheimer's disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Ribosylation triggering Alzheimer's disease-like Tau hyperphosphorylation via activation of CaMKII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Tyrosine nitration within the proline-rich region of Tau in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

A plasmonic chip for biomarker discovery and diagnosis of type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

New criteria for frontotemporal dementia syndromes: clinical and pathological diagnostic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant tau

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Phosphorylated Tau interacts with c-Jun N-terminal kinase-interacting protein 1 (JIP1) in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Advances in therapeutics for neurodegenerative tauopathies: moving toward the specific targeting of the most toxic tau species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Toxic tau oligomer formation blocked by capping of cysteine residues with 1,2-dihydroxybenzene groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Analysis of tau post-translational modifications in rTg4510 mice, a model of tau pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Structural and functional changes in tau mutant mice neurons are not linked to the presence of NFTs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Tau suppression in a neurodegenerative mouse model improves memory function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Neurofibrillary tangle-bearing neurons are functionally integrated in cortical circuits in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

The amyloid hypothesis of Alzheimer's disease at 25 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

The CAMKK2-AMPK kinase pathway mediates the synaptotoxic effects of Aβ oligomers through Tau phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Amyloid-β and tau--a toxic pas de deux in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Tau-mediated NMDA receptor impairment underlies dysfunction of a selectively vulnerable network in a mouse model of frontotemporal dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

The Dynamics and Turnover of Tau Aggregates in Cultured Cells: INSIGHTS INTO THERAPIES FOR TAUOPATHIES.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Protein structural and surface water rearrangement constitute major events in the earliest aggregation stages of tau.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Internalized Tau Oligomers Cause Neurodegeneration by Inducing Accumulation of Pathogenic Tau in Human Neurons Derived from Induced Pluripotent Stem Cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Tau promotes neurodegeneration via DRP1 mislocalization in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

NH2-truncated human tau induces deregulated mitophagy in neurons by aberrant recruitment of Parkin and UCHL-1: implications in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Tau accumulation impairs mitophagy via increasing mitochondrial membrane potential and reducing mitochondrial Parkin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Tau promotes neurodegeneration through global chromatin relaxation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

The unfolded protein response affects neuronal cell cycle protein expression: implications for Alzheimer's disease pathogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Reconsider Alzheimer's disease by the 'calpain-cathepsin hypothesis'--a perspective review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Targeting microglia for the treatment of Alzheimer's Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Staging of Alzheimer's disease-related neurofibrillary changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Invited review: Prion-like transmission and spreading of tau pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Self-propagation of pathogenic protein aggregates in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Propagation of tau pathology in a model of early Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Brain homogenates from human tauopathies induce tau inclusions in mouse brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Extracellular Vesicles Isolated from the Brains of rTg4510 Mice Seed Tau Protein Aggregation in a Threshold-dependent Manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Neuronal activity enhances tau propagation and tau pathology in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Removing endogenous tau does not prevent tau propagation yet reduces its neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Methylene blue fails to inhibit Tau and polyglutamine protein dependent toxicity in zebrafish

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Inhibition of tau aggregation in a novel Caenorhabditis elegans model of tauopathy mitigates proteotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Complex Disposition of Methylthioninium Redox Forms Determines Efficacy in Tau Aggregation Inhibitor Therapy for Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Nontoxic singlet oxygen generator as a therapeutic candidate for treating tauopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

21 January 2018

The many faces of tau

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Loss of MAP function leads to hippocampal synapse loss and deficits in the Morris Water Maze with aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

No Overt Deficits in Aged Tau-Deficient C57Bl/6.Mapttm1(EGFP)Kit GFP Knockin Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Tau reduction prevents disease in a mouse model of Dravet syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Tau silencing by siRNA in the P301S mouse model of tauopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Antisense reduction of tau in adult mice protects against seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

miR-132/212 deficiency impairs tau metabolism and promotes pathological aggregation in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Reduction of Nuak1 Decreases Tau and Reverses Phenotypes in a Tauopathy Mouse Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Tau immunotherapy for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Antibody uptake into neurons occurs primarily via clathrin-dependent Fcγ receptor endocytosis and is a prerequisite for acute tau protein clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Distinct Therapeutic Mechanisms of Tau Antibodies: Promoting Microglial Clearance Versus Blocking Neuronal Uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Affinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Identification and characterization of natural antibodies against tau protein in an intravenous immunoglobulin product.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Intravenous immunoglobulin reduces tau pathology and preserves neuroplastic gene expression in the 3xTg mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Effects of tau domain-specific antibodies and intravenous immunoglobulin on tau aggregation and aggregate degradation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Inhibition of JNK by a peptide inhibitor reduces traumatic brain injury-induced tauopathy in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Site-specific phosphorylation of tau inhibits amyloid-β toxicity in Alzheimer's mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Diaminothiazoles modify Tau phosphorylation and improve the tauopathy in mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Ginsenoside Rd attenuates beta-amyloid-induced tau phosphorylation by altering the functional balance of glycogen synthase kinase 3beta and protein phosphatase 2A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Reversing EphB2 depletion rescues cognitive functions in Alzheimer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Stimulation of EphB2 attenuates tau phosphorylation through PI3K/Akt-mediated inactivation of glycogen synthase kinase-3β.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Evidence for irreversible inhibition of glycogen synthase kinase-3β by tideglusib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Pharma pumps up anti-tau Alzheimer pipeline despite first Phase III failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Blockade of Tau hyperphosphorylation and Aβ₁₋₄₂ generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and σ₁ receptor agonist, in a nontransgenic mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Fyn inhibition rescues established memory and synapse loss in Alzheimer mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Rho Kinase Inhibition as a Therapeutic for Progressive Supranuclear Palsy and Corticobasal Degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Structure guided design of a series of selective pyrrolopyrimidinone MARK inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

PP2A mRNA expression is quantitatively decreased in Alzheimer's disease hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Sodium selenate retards epileptogenesis in acquired epilepsy models reversing changes in protein phosphatase 2A and hyperphosphorylated tau.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Sodium selenate reduces hyperphosphorylated tau and improves outcomes after traumatic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Acetylation of tau inhibits its degradation and contributes to tauopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Acetylated Tau Obstructs KIBRA-Mediated Signaling in Synaptic Plasticity and Promotes Tauopathy-Related Memory Loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

HDAC6 mutations rescue human tau-induced microtubule defects in Drosophila.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Prevention of Alzheimer's disease: Omega-3 fatty acid and phenolic anti-oxidant interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Curcumin improves tau-induced neuronal dysfunction of nematodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Pharmacologic inhibition of 5-lipoxygenase improves memory, rescues synaptic dysfunction, and ameliorates tau pathology in a transgenic model of tauopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Pharmacologic blockade of 12/15-lipoxygenase ameliorates memory deficits, Aβ and tau neuropathology in the triple-transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Activation of autophagy by rapamycin does not protect oligodendrocytes against protein aggregate formation and cell death induced by proteasomal inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Fisetin stimulates autophagic degradation of phosphorylated tau via the activation of TFEB and Nrf2 transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

BAG3 facilitates the clearance of endogenous tau in primary neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Tau protein function in living cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Microtubules (tau) as an emerging therapeutic target: NAP (davunetide).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

NAP (davunetide) rescues neuronal dysfunction in a Drosophila model of tauopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Specific calpain inhibition by calpastatin prevents tauopathy and neurodegeneration and restores normal lifespan in tau P301L mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Calpain inhibitor A-705253 mitigates Alzheimer's disease-like pathology and cognitive decline in aged 3xTgAD mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Neuroprotective effects of Cerebrolysin in triple repeat Tau transgenic model of Pick's disease and fronto-temporal tauopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Intraperitoneal Administration of a Novel TAT-BDNF Peptide Ameliorates Cognitive Impairments via Modulating Multiple Pathways in Two Alzheimer's Rodent Models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Dysregulation of microRNA-219 promotes neurodegeneration through post-transcriptional regulation of tau

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Ceftriaxone ameliorates tau pathology and cognitive decline via restoration of glial glutamate transporter in a mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Metformin promotes tau aggregation and exacerbates abnormal behavior in a mouse model of tauopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Ultrasound treatment of neurological diseases--current and emerging applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Scanning ultrasound removes amyloid-β and restores memory in an Alzheimer's disease mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Blood-brain barrier breakdown in the aging human hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Accelerated pericyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Lack of Widespread BBB Disruption in Alzheimer's Disease Models: Focus on Therapeutic Antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Pittsburgh Compound-B (PiB) binds amyloid β-protein protofibrils

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Characteristics of Tau and Its Ligands in PET Imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

PET Imaging of Tau Deposition in the Aging Human Brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Association of In Vivo [18F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Tau Rather than TDP-43 Proteins are Potential Cerebrospinal Fluid Biomarkers for Frontotemporal Lobar Degeneration Subtypes: A Pilot Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Detection of the tau protein in human serum by a sensitive four-electrode electrochemical biosensor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Personalised and Precision Medicine in Cancer Clinical Trials: Panacea for Progress or Pandora's Box?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Challenges, solutions, and recommendations for Alzheimer's disease combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Animal models of Alzheimer's disease and frontotemporal dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Truncated tau deregulates synaptic markers in rat model for human tauopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Sustained high levels of neuroprotective, high molecular weight, phosphorylated tau in the longest-lived rodent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Does age matter? The impact of rodent age on study outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Mobility and subcellular localization of endogenous, gene-edited Tau differs from that of over-expressed human wild-type and P301L mutant Tau

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Calpain Activation in Alzheimer's Model Mice Is an Artifact of APP and Presenilin Overexpression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

How iPS cells changed the world

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

A three-dimensional human neural cell culture model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Widespread tau seeding activity at early Braak stages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Proteopathic tau seeding predicts tauopathy in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Brain Aggregates: An Effective In Vitro Cell Culture System Modeling Neurodegenerative Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Disaggregation of Alzheimer beta-amyloid by site-directed mAb.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Open questions for Alzheimer's disease immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Amyloid-β peptide-specific DARPins as a novel class of potential therapeutics for Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Neuropathological stageing of Alzheimer-related changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

MRI is a sensitive marker of subtle white matter pathology in hypoperfused mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Phosphorylation of tau by glycogen synthase kinase-3β in intact mammalian cells: The effects on the organization and stability of microtubules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

A spatial gradient of tau protein phosphorylation in nascent axons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Nrf2 reduces levels of phosphorylated tau protein by inducing autophagy adaptor protein NDP52.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

"Lest we forget you--methylene blue...".

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

A phase II trial of tideglusib in Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Rapamycin ester analog CCI-779/Temsirolimus alleviates tau pathology and improves motor deficit in mutant tau transgenic mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Stem-cell discovery platforms yield first clinical candidates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

Antibodies to beta-amyloid decrease the blood-to-brain transfer of beta-amyloid peptide.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.155

7 January 2021

inferred from DOI database lookup

C-terminal inhibition of tau assembly in vitro and in Alzheimer's disease.

1 reference

12 December 2020

Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimer's disease treatment

1 reference

12 December 2020

The role of extracellular Tau in the spreading of neurofibrillary pathology.

1 reference

12 December 2020

Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease.

1 reference

12 December 2020

Revolutionizing Alzheimer's disease and clinical trials through biomarkers

1 reference

12 December 2020

PTL-1, a microtubule-associated protein with tau-like repeats from the nematode Caenorhabditis elegans

1 reference

12 December 2020

The relationship between truncation and phosphorylation at the C-terminus of tau protein in the paired helical filaments of Alzheimer's disease

1 reference

12 December 2020

A prospective pilot study on serum cleaved tau protein as a neurological marker in severe traumatic brain injury

1 reference

12 December 2020

Co-immunoprecipitation with Tau Isoform-specific Antibodies Reveals Distinct Protein Interactions and Highlights a Putative Role for 2N Tau in Disease

1 reference

12 December 2020

PRECISION MEDICINE - The Golden Gate for Detection, Treatment and Prevention of Alzheimer's Disease

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD.2017.155

1 reference

4 February 2018

PubMed ID

28983098

1 reference

4 February 2018